Early‐phase clinical trials have assessed the efficacy of IL6R‐blocking antibodies in EOC patients, pioneered by the assessment of tocilizumab combined with interferon‐alpha or siltuximab in patients with chemoresistant ovarian cancer, showing promising response rates [22, 44, 45]. The gene discussed is IL6R; the disease is ovarian carcinoma.